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Abstract
Background: Whether or not there is a relationship between use of mobile phones (analogue and digital cellulars,
and cordless) and head tumour risk (brain tumours, acoustic neuromas, and salivary gland tumours) is still a matter
of debate; progress requires a critical analysis of the methodological elements necessary for an impartial evaluation
of contradictory studies.
Methods: A close examination of the protocols and results from all case-control and cohort studies, pooled- and
meta-analyses on head tumour risk for mobile phone users was carried out, and for each study the elements
necessary for evaluating its reliability were identified. In addition, new meta-analyses of the literature data were
undertaken. These were limited to subjects with mobile phone latency time compatible with the progression of
the examined tumours, and with analysis of the laterality of head tumour localisation corresponding to the
habitual laterality of mobile phone use.
Results: Blind protocols, free from errors, bias, and financial conditioning factors, give positive results that reveal a
cause-effect relationship between long-term mobile phone use or latency and statistically significant increase of
ipsilateral head tumour risk, with biological plausibility. Non-blind protocols, which instead are affected by errors,
bias, and financial conditioning factors, give negative results with systematic underestimate of such risk. However,
also in these studies a statistically significant increase in risk of ipsilateral head tumours is quite common after
more than 10 years of mobile phone use or latency. The meta-analyses, our included, examining only data on
ipsilateral tumours in subjects using mobile phones since or for at least 10 years, show large and statistically
significant increases in risk of ipsilateral brain gliomas and acoustic neuromas.
Conclusions: Our analysis of the literature studies and of the results from meta-analyses of the significant data
alone shows an almost doubling of the risk of head tumours induced by long-term mobile phone use or latency.
Background
The worldwide spread of the use of MPs (mobile
phones: analogue and digital cellulars, and cordless) has
heightened concerns about possible adverse effects,
especially head tumours. According to the International
Telecommunications Union, the number of cell-phone
subscriptions has reached 5 billion (mid 2010), with
more than half of all users believed to be children and
young adults. There are no data for cordless users, but a
figure of 2 billion is a reasonable assumption. Given
these numbers, even an established modest increase (20-
30%) in tumour risk for MP users would result in signif-
icant social and health costs and individual suffering,
while higher risks could give rise to a health crisis of
dramatic proportions. While most technologies carry
risks, these should be assessed accurately and
responsibly.
MPs were introduced onto the market in the 1980s,
and widely used for the following decade in the USA,
the Scandinavian countries and Israel. Since the begin-
ning of 1990s MPs have become widespread in many
other countries too, with the consequence that there has
been exposure to MP radiation throughout almost the
entire world for at least 20 years [1-3]. Although brain
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times (up to 30 years or more), it is likely that - as
found with long-latency tumours due to ionizing radia-
tions, asbestos or smoking - some due to MP will be
diagnosed after just 10-15 years of MP use or latency.
The case-control studies by the Hardell group in Sweden
report a statistically significant increase of at least 100% in
risk of ipsilateral cerebral cancers (astrocytomas, a highly
invasive glioma sub-type) and of benign tumours of the
acoustic nerve (neuromas) among MP users, after use or
latency period ≥ 10 years [1-3]. It is therefore vital to
understand the weight of the conflicting data from other
studies which are considered reassuring in their failure to
find any increased risk of head tumours in MP users [4,5].
Methods
We have carried out a critical examination of the proto-
cols and results from all case-control and cohort studies,
pooled analyses and meta-analyses on head tumour risk
among MP users. For each study we have identified the
elements that must be taken into account to ensure an
impartial evaluation of its reliability, that is: a) the num-
ber of subjects selected (cases and controls), and the per-
centage of their participation in the study; b) the
percentage of actually exposed subjects, based on the fre-
quency and duration of the MP use; c) the inclusion
among the exposed of all users of MPs, cordless included;
d) the latency and/or exposure time since first use of
MPs; e) the laterality of the head tumour localization
relative to the habitual laterality of MP use; f) the distri-
bution of the relative risk (odds ratio, OR) values above
and under 1, their statistical significance [95% confidence
interval (95% CI) limits], and the probability that such
distribution might be casual; g) the full and correct selec-
tion and citation of data included in the meta-analyses.
We have quantified the total number of OR values
from each study, independently of sex, age, exposure
time or latency of the examined subjects. Since the OR
estimates reported by each author are not independent,
a statistical comparison between the percentages of ORs
> 1 or < 1 is difficult. However, a simple comparison of
their percentage may indicate if their differences are
more or less random, and might be due to a signifi-
cantly increased risk or a substantial protective effect, or
else - in the absence of plausibility of either of these
effects - to errors and/or distortions in the study design.
In order to be included in our meta-analyses, studies
had to have met all the following criteria:
￿ published in peer-reviewed journals;
￿ included participants using MPs since ≥ 10 years;
￿ incorporated a laterality analysis of tumours.
The hypothesis test for presence of heterogeneity was
based on the Q test of heterogeneity, which follows a c
2
distribution. Furthermore, two measures for quantifying
the impact of heterogeneity were calculated: H
2 (square
root of the Q heterogeneity statistic divided by its
degrees of freedom) and Higgins I
2 (transformation of H
that describes the proportion of total variation in study
estimates that is due to heterogeneity). If heterogeneity
was observed, then the random-effect model was per-
formed by incorporating an estimate of the between-
study heterogeneity (DerSimonian and Laid τ
2)i n t ot h e
weights. When the general fixed effect model was
applied to each study estimate, a weight directly propor-
tional to its precision was given (inverse variance-
weighted method) [6].
Results
MPs and head tumours: positive data
An overview of the most significant results obtained by
the Hardell group in the three pooled analyses of their
data through case-control epidemiological studies refer-
ring to tumours diagnosed during 1997-2003 is given in
Table 1 [1-3] With ≥ 10-year MP use or latency, a sta-
tistically significant (s.s.) increase (ca 2- to 4-fold) in risk
of overall (ipsi- plus contralateral) malign and benign
brain tumours and acoustic neuromas is shown after
use of analogue and digital cellulars. With cordless
p h o n eu s e ,i n s t e a d ,r i s ki sa b o u td o u b l e ,s . s .o n l yf o r
malign brain tumours (Table 1).
As Table 1 shows, the tumour increase is chiefly loca-
lized on the habitual-use side of the head (ipsilateral
tumours), and is very marked (up to 3-5 times normal
incidence) and s.s. for malign brain tumours and acous-
tic neuromas with cellular phone use, and for astrocyto-
mas and meningiomas with cordless use. The data for
overall tumours are lower, though still considerable (up
to 2-3 times normal incidence) and s.s., while the risk of
contralateral tumours is not s.s., except for astrocytoma
following use of cellular phones. According to Hardell,
this latter finding results from the fact that the radiation
produced by MPs - despite being much lower on the
contralateral side - is still significant in the ventricular
and subventricular space from which gliomas and (their
subtype) astrocytomas originate, such that these can
develop also to the contralateral side. Finally, the
increase in risk of cerebral astrocytomas and acoustic
neuromas, in particular ipsilateral, is higher in the sub-
group that started using MPs at an age <20 years, even
if the 95%CIs are very broad, owing to the still-limited
number of subjects being studied (Table 1).
It should be stressed that a greater increase in ipsilateral
tumours than in total tumours, but absence of increase in
contralateral tumours, is precisely what would be expected
in the case of MPs having oncogenic action [4,5].
A detailed analysis of the data from Hardell’s seven
most recent studies [7-10], including the pooled analyses
[1-3], shows that (see additional file 1):
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study is always very high (84-91%) for both cases and
controls;
￿ the percentages of people exposed are sizeable
(mean = 60%, but - in a few studies - up to 70-80%) for
both cases and controls;
￿ MP use is significant: 194 cases used MPs for more
than 1000 hours, and 85 for more than 2000 hours, for
at least 10 years (i.e. from > 16 to just > 32 min/day);
￿ the percentages of cases and controls exposed for at
least 10 years are 18% and 13% of the total number of
exposed cases and controls;
￿ of the total OR values reported in the above studies,
over 90% are > 1, 37% of which are s.s., and the prob-
ability of this highly asymmetrical distribution of OR
values being due to chance is almost zero (Figure 1A).
This pattern indicates that the results are not due to
errors or conditioning in the protocol Hardell used,
since in other reports regarding other types of tumour
(salivary glands [11] and testicles [12]) in MP users -
due to the very limited number of those exposed for at
least 10 years - no s.s. risk increase is found, nor is
there any clear prevalence of OR values > 1. Only for
non-Hodgkin lymphomas [13] a s.s. risk increase is
found and the distribution of OR values is shifted
towards values > 1 (73%), with low probability of this
being due to chance (Figure 1A);
￿ the increased risk in MP users is not limited to glio-
mas, meningiomas and acoustic neuromas, but involves
also other types of head tumour -low grade and high
grade astrocytomas, oligodendrogliomas, medulloblasto-
mas, ependimomas, and other/mixed malignant
tumours; pituitary adenomas and other/mixed benign
brain tumours - which are considered separately [3].
In the Hardell group studies [1-3,7-10,14] a dose/
response relationship and thus the existence of a cause-
effect relationship are documented by the fact that:
￿ the risk of developing tumours is prevalent, if not
exclusive, on the head side habitually exposed to MP
radiation (ipsilateral);
￿ the trend for increase in OR as a function of time of
MP use is s.s.;
￿ the risk is higher in rural areas [15], where the signal
required for optimal use of cellular phones is often very
limited owing to the low number of base-stations, and
the compensatory emission of the cell-phone battery is
particularly high (up to 80 V/m or more) compared
with urban areas where the signal is almost always
Table 1 Results from the case-control studies by Hardell.
tumours analogue digital cordless
brain malign (82/84): 2.4; 1.6-3.4 (19/18): 2.8; 1.4-5.7 (33/45): 1,8; 1,1-3.0
only astrocytomas I-IV (59/84): 2.7; 1.8-4.2 (15/18): 3.8; 1.8-8.1 (23/45): 2.2; 1.3-3.9
brain benign (57/84): 1.8; 1.2-2.6 (13/18): 1.6; 0.8-3.5 (28/45): 1.4; 0.8-2.3
only meningiomas (34/84): 1.6; 1.02-2.5 (8/18): 1.3; 0.5-3.2 (23/45): 1.6; 0.9-2.8
acoustic neuromas (19/84): 3.1; 1.7-5.7 (1/18): 0.6; 0.1-5.0 (4/45): 1.0; 0.3-2.9
Idem, but also as a function of head tumour laterality [3] (≥ 10-year latency)
tumours MP type all ipsilateral contralateral
astrocytomas analogue + digital (78/99): 2.7; 1.8-3.9 (50/45): 3.3; 2.0-5.4 (26/29): 2,8; 1,5-5.1
″ cordless (28/45): 2.5; 1.4-4.4 (19/15): 5.0; 2.3-11.0 (8/20): 1.4; 0.6-3.5
others malign analogue + digital (8/99): 3.2; 1.2-8.8 (4/45): 4.1; 1.03-16.0 (1/29): 1.7; 0.2-15.0
″ cordless (1/45): 1.1; 0.1-10.0 - not analysed (1/20): 3.9; 0.3-44.0
neuromas analogue + digital (20/99): 2.9; 1.6-5,5 (13/45): 3.0: 1.4-6.2 (6/29): 2.4; 0.9-6.3
″ cordless (4/45): 1.3; 0.4-3.8 (3/15): 2.3; 0.6-8.8 (1/20): 0.5; 0.1-4.0
meningiomas analogue + digital (38/99): 1.5; 0.98-2.4 (18/45): 1.6; 0.9-2.9 (12/29): 1.6; 0.7-3.3
″ cordless (23/45): 1.8; 1.01-3.2 (11/15): 3.0; 1.3-7.2 (7/20): 1.1; 0.5-2.9
Idem, only individuals who started using MPs < 20-year old (≥ 1-year latency) [3,16]
tumours MP type all ipsilateral contralateral
astrocytomas analogue + digital (15/14): 5.2; 2.2-12.0 (8/5): 7.8; 2.2-28.0 (2/4): 2.2; 0.4-13.0
″ cordless (14/16): 4.4; 1.9-10.0 (9/6): 7.9; 2.5-25.0 (1/4): 1.1; 0.1-10.0
neuromas analogue + digital (5/14): 5.0; 1.5-16.0 (3/5): 6.8; 1.4-34.0 (1/4): 2.4; 0.2-24.0
″ cordless (1/16): 0.7; 0.1-5.9 (1/6): 1.7; 0.2-16.0 - not analysed
Results of the pooled analyses by Hardell [1-3] on the risk of overall head tumours in exposed subjects compared to that of non-MP-users, as a function of the
use of different MP types, (no. of cases and controls with ≥ 10-year use or latency): OR; 95%CI.
95% s.s. data.
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or even less);
￿ the combined use of various types of MP raises the
risk of developing head tumours;
￿ the risk of head tumour is higher in those starting
MP use when aged below 20 years [3,16] (see also Table
1).
The biological plausibility of the oncogenic action of
the EM radiation emitted by the MPs is supported by a
considerable amount of experimental data [17-19]. This
radiation, in fact, can produce a variety of effects able to
cause or contribute to the neoplastic cell transformation:
￿ genetic alterations (DNA damage, chromosomal
aberrations, micronuclei, sister-chromatid exchanges
and gene mutations) in cells irradiated in vitro (includ-
ing germinal and cerebral cells) [20,21]; in animals
exposed in the laboratory [22,23] or natural environ-
ment [24], and in MP users [25];
￿ induction of DNA reparative synthesis and altera-
tions in transcription of DNA, activation of oncogenes
and other epigenetic effects [26,27];
￿ alteration of the blood-brain barrier permeability and
brain neuron damage [28,29];
￿ induction of heat-shock proteins and apoptosis that
stress living cells [30,31];
￿ reduction of melatonin synthesis and activation of
Fenton’s reaction which increase the concentration of
free radicals and peroxides able to damage the DNA
[20,32];
￿ alteration of functionality, count and form of sperms
in MP users whose phone stays on and in their trouser
pockets during the call [33,34].
It should be noticed that many studies on biological
effects of MP use are negative, but for the major part
were conditioned having been funded by the cell-phone
industry [35] (see Discussion).
MPs and head tumours: negative data
Between 2000 and 2002 three case-control studies were
published - two were funded by MP companies [36,37],
while in one no information was given about how the
study was funded [38]. The findings indicated no
increase in risk of brain or acoustic nerve tumour asso-
ciated with MP use. However, there was complete
absence of subjects exposed for at least 10 years, and
the maximum latency period was only 4-5 years (see
additional file 2).
On this basis, it is small wonder that there is a com-
plete absence of increase in brain or acoustic tumour
risk; quite the contrary: most OR values (67-85% of 122
total ORs ≠ 1) were < 1, and the probability of this
being chance is very low or almost zero (Figure 1D).
Since 2004, 17 case-control epidemiological studies
have been published under the Interphone project
Figure 1 Hardell and Interphone data: percentage of the OR values > 1 or < 1, and percentage of those statistically significant.
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Cancer (IARC) in 2000 [39-55], and overall are consid-
ered to lack any evidence for increase in head tumours
in MP users. However, examination of all the above
“negative” studies shows that there are bias, confounding
factors, and errors in the methodological approach and
the data processing and presentation. These factors
include (see additional file 3):
￿ the low participation of cases or controls: ≤ 50%
[43,44,46,50,54], ≤ 60% [45,52,55], ≤ 70%
[39,42,47-49,53], not even given [37];
￿ the low percentages of exposed cases or controls: ≤
30% [36-38], ≤ 40% [47,52], ≤ 50% [39,42,49,54], ≤ 60%
[40,41,43,45,46,48,50,51,53,55], not even given [44];
￿ the low percentages of cases or controls exposed for
≥ 10 years: 0% [36-38,45,49,52,53], ≤ 5% [39,47,51,55], ≤
10% [40-42,46,48], not even given [44];
￿ the inadequate definition for “normal use of cell
phones” as “at least 1 phone call per week, for at least 6
months”. Therefore, if a risk exists, it is “diluted”
because of the dominance, in the examined sample, of
subjects exposed too little: the average daily use of MPs
in subjects considered “exposed” by Interphone is just
2-5 minutes per day, very scarcely representative of the
intensive use made of cellphones today;
￿ the failure to include cordless users who, although
exposed, are included among the non-exposed. The
Interphone authors justify the exclusion of cordless
users through the postulation that the intensity of the
EM emission of this type of MP should be irrelevant
and in any case much lower than emissions from cell
phones, but in fact quite the reverse is true
[1-3,9,10,56], to the extent that significant increases in
the incidence of malign and benign brain tumours are
found by Hardell also in those using only cordless
phones (Table 1).
￿ the relative prevalence in controls exposed over the
non-exposed subjects which is due to the fact that,
there being no blind protocol, the subjects interviewed
knew what was the purpose of the study. Therefore, MP
users willingly elect to participate in the study, aware of
its goals, while non-users tend to decline. This “selection
bias” is recognized by the Interphone authors them-
selves, but in their view it does not cause reduction in
OR of more than 10% [44,57], which is true for the
overall Interphone data, but in some studies this bias
alone can result in a more significant reduction in OR
assessment: ≥ 15% [45,55], ≥ 25% [39,41,42], ≥ 30%
[37,38,52,54], ≥ 50% [36] (see additional file 4).
In the negative cohort studies [58-61], where exposure
is based simply on the fact that subjects work for an
industry that produces MPs or are mobile telephony
company subscribers (i.e. without the need to question
participants), and where the illness/mortality incidence
data estimate is based on linkage of data from people
exposed with data from national tumour registers, there
is an overabundance of data showing a reduced risk of
those exposed - in all subjects [58,61] or only in males
[59,60] - often s.s. and with very little probability of
being chance (Figure 1E, see additional file 5). In these
studies the s.s. reduction in risk even concerns organs
that most certainly cannot be irradiated during the calls,
in particular lung, stomach, liver and pancreas, and also
the mortality from all causes, cardiac problems, liver cir-
rhosis, and car accidents. Clearly, the above “healthy
worker effect” is due to systematic methodological
errors and bias, e.g. the low prevalence of long expo-
sures or latencies or the inadequate definition of cell-
phone use.
In the negative case-control studies [36-55] the combi-
nation of all the above factors leads to strong underesti-
mation of the risk, and together act such that the
majority of OR values are < 1, often s.s. (Figure 1B):
￿ in the 17 Interphone studies, out of 1084 OR values
different from 1, 76% are < 1 and only 24% are > 1:
￿ t h ep r e v a l e n c eo fO Rv a l u e s<1i se x t r e m e l yu n u -
sual: = 100% [44], ≥ 90% [41,54], ≥ 80% [45-47,49,52], ≥
70% [39,42], ≥ 60% [43,48,51,55];
￿ the probability of this asymmetric distribution of
OR being chance in 6 of these studies is low
[39,42-44,48,51], while in another 5 [41,46,47,49,54], as
in the overall data, it is practically zero;
￿ Lloyd-Morgan [62] applied a probability test to a
distribution identical to that above, obtained by examin-
ing a lower number of OR values from 11 of the Inter-
phone studies 76% OR < 1 and 24% OR > 1), and found
the probability of this being chance to be 6.2 × 10
-20;
￿ even more extraordinary, the OR values in 4 studies
fall off with increased duration of exposure to MPs and/
or latency time [36,39,48,52].
Discarding the idea of this being due to a protective
effect from head tumour risk effected by MP use (not
supported by experimental data - indeed, not even the
Interphone authors support it), the only explanation can
be found from a strong reduction in the assessment of
risk resulting from the methodological errors present in
the Interphone protocol.
The Interphone researchers themselves have published
various studies on the methodological bias and flaws
present in their work [44,57,63]. Most of the errors are
attributed to the fact that the exposure is assessed on
the basis of the data self-reported by participants in the
case-control study ("recall errors”): in particular, it has
been claimed that the increased risks reported in some
studies (Table 2) could be due to cases blaming MPs as
the cause of the disease. However, recently Hardell pub-
lished the results of a case-control study on mortality
(not incidence) due to malignant brain tumours in
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view could be performed, and found that use of analo-
gue or digital cell-phones gave a s.s. increased risk,
highest in the > 10 year latency group (OR = 2.4; 95%CI
= 1.4-4.1), increasing with cumulative number of life-
time hours of cellular use and being highest in the >
2000 h group (OR = 3.4; 95% CI = 1.6-7.1) [64].
Hardell versus Interphone
The low number of cases with ≥ 10 years latency in the
above negative studies is confirmed by data given in the
last Interphone Study Results update [65]:
￿ only 54% of overall cases with “regular since ever
use” (≥ 1 call/week for ≥ 6 months);
￿ only 5% of overall cases actually exposed for ≥ 10
years;
￿ only 2% of overall ipsilateral actually exposed for ≥
10 years;
￿ while OR < 1 predominate in data referring to “regu-
lar use” of cell-phones (85%, of which 22% s.s.), the OR
distribution clearly shiftst o w a r d sv a l u e s>1f o ro n l y
ipsilateral tumours with ≥ 10-years of cellular use or
latency (86%, of which 25% s.s.), with the percentage of
s.s. OR > 1 decreasing to 12% for total tumours and fall-
ing to 0% for contralateral tumours (Figure 1C, see addi-
tional file 6).
Moreover, in some of the Interphone studies s.s.
increases in risk for ipsilateral tumours are quite
Table 2 Increased OR values in the Interphone studies on relationships between MP use and head tumours
Author (tumour type) year ref. years MP use total tumours cases/
controls and OR
(95%CI)
ipsilateral tumours
cases/controls and OR
(95%CI)
contralateral tumours
cases/controls and OR
(95%CI)
Lonn et al. 2004 40 since ≥ 10 14/29 1.9 (0.9-4.1) 12/15 3.9 (1.6-9.5) 4/17 0.8 (0.2-2.9)
(acoustic neuromas) for ≥ 10 11/26 1.6 (0.7-3.6) 9/12 3.1 (1.2-8.4) 4/16 0.8 (0.2-3.1)
Schoemaker et al. 2005 43 since ≥ 10 47/212 1.0 (0.7-1.5) 31/124 1.3 (0.8-2.0) 20/105 1.0 (0.6-1.7)
(acoustic neuromas) for ≥ 10 31/131 1.1 (0.7-1.8) 23/72 1.8 (1.1-3.1) 12/73 0.9 (0.5-1.8)
Lonn et al. 2005 41 since ≥ 10 25/38 0.9 (0.5-1.5) 15/18 1.6 (0.8-3.4) 11/25 0.7 (0.3-1.5)
(gliomas) for ≥ 10 22/33 0.9 (0.5-1.6) 14/15 1.8 (0.8-3.9) 9/23 0.6 (0.3-1.4)
(meningiomas) since ≥ 10 12/36 0.9 (0.4-1.9) 5/18 1.3 (0.5-3.9) 3/22 0.5 (0.1-1.7)
for ≥ 10 8/32 0.7 (0.3-1.6) 4/15 1.4 (0.4-4.4) 3/23 0.5 (0.1-1.8)
Hepworth et al. 2006 46 since ≥ 10 66/112 0.9 (0.6-1.3)
(gliomas) for ≥ 10 48/67 1.14 (0.74-1.73)
regular use 278/486 1.24 (1.02-1.52) 199/491 0.75 (0.61-0.93)
Schuz et al. 2006 47 females only ≥ 0.5 30/38 1.96 (1.1-3.5)
(gliomas)
Lonn et al. 2006 48 since ≥ 10 7/15 1.4 (0.5-3.9) 6/9 2.6 (0.9-7.9) 1/9 0.3 (0.0-2.3)
(parotid gland tumours) for ≥ 10 5/13 1.1 (0.4-3.6) 4/8 2.0 (0.5-7.0) 1/8 0.3 (0.0-2.6)
Klaeboe et al. 2007 49 since ≥ 6 70/73 0.8 (0.5-1.2) 39/37 1.3 (0.8-2.1) 32/42 0.8 (0.5-1.4)
(gliomas) for ≥ 6 55/61 0.7 (0.4-1.2) 30/30 1.2 (0.7-2.1) 27/34 0.9 (0.5-1.5)
Lahkola et al. 2007 50 since ≥ 10 143/220 0.95 (0.74-1.23) 77/117 1.39 (1.01-1.92) 67/121 0.98 (0.71-1.37)
(gliomas) for ≥ 10 88/134 0.94 (0.69-1.78) 43/74 1.14 (0.76-1.72) 41/71 1.01 (0.67-1.53)
Lahkola et al. 2008 54 since ≥ 10 73/212 0.91 (0.67-1.25) 33/113 1.05 (0.67-1.65) 24/117 0.62 (0.38-1.03)
(meningiomas) for ≥ 10 42/130 0.85 (0.57-1.26) 21/73 0.99 (0.57-1.73) 13/68 0.64 (0.33-1.23)
Interphone 2010 72 ≥ 1640 calls 160/113 1.82 (1.15-2.89) 100/62 1.96 (1.22-3.16) 39/31 1.25 (0.64-2.42)
(gliomas)
Sadetzki et al. 2008 53 > 5479 calls 86/157 1.13 (0.79-1.61) 121/159 1.58 (1.11-2.24) 46/135 0.78 (0.51-1.19)
(parotid gland tumours) > 266.3 hours 80/155 1.03 (0.72-1.47) 115/158 1.49 (1.05-2.13) 48/129 0.84 (0.55-1.28)
> 5479 calls <5-year latency 47/82 1.16 (0.74-1.82) 35/40 1.80 (1.05-3.10) 12/41 0.63 (0.31-1.30)
“ > 5479 calls >5-year latency 120/215 1.08 (0.77-1.50) 86/119 1.50 (1.03-2.20) 34/94 0.84 (0.52-1.34)
only regular users > 5479 calls 86/157 1.48 (1.05-2.10)
“ > 18997 calls 81/140 1.51 (1.05-2.17)
“ > 1035 cumulative calls 83/134 1.50 (1.04-2.16)
≥ 18997 calls, urban areas 49/99 1.00 (0.65-1.55)
“ rural areas 32/41 1.81 (1.04-3.14)
≥ 1035 hours, urban areas 51/96 1.02 (0.67-1.58)
“ rural areas 32/38 1.96 (1.11-3.44)
95% s.s. data.
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Page 6 of 15common in people having used MPs since or for ≥ 10
years, and - more generally - even when there is no sig-
nificant evidence of risk, a clear increase in OR values is
often seen considering the figure for ipsilateral rather
than total tumours, while there is a net fall for just con-
tralateral tumours (Table 2). Taking into consideration
the systematic underestimation of OR values in the
Interphone studies, this is a clear indicator of probable
carcinogenic risk.
The meta-analysis of Ahlbom [4] includes some of the
US studies [36,37] and some of Hardell’s earlier data
(1999, 2001, 2002, not quoted in the present review) on
risks of glioma, clearly lacking cases with ≥ 10-year
latency time. Moreover it reports from Hardell [8] only
data selectively chosen for subjects with “ever/never
use” (> 5 year latency) but not, among those with 10
years since first use, the much more significant increases
of risks, although these are clearly indicated in Hardell’s
paper analogue, digital, and cordless phone use. This
meta-analysis shows data overall lacking any indication
of carcinogenic risk, but underlines the absolute incom-
patibility between the two data sources: 83% of Hardell’s
risk data (OR) are > 1, 43% of which s.s., while the
Interphone data are largely < 1 (73%), 11% of which s.s.
(Figure 1C, see additional file 6).
In contrast, the meta-analyses of Hardell [14,66],
Kundi [5], and Khurana [67] including the literature
data on ipsilateral head tumours in people having used
MPs since or for ≥10 years - and so also part of the
Interphone data [40,43,46,50] - show large and s.s.
increases (100%) for the risk of ipsilateral astrocytomas
with high level of malignancy, and sizable and s.s.
increases (50-140%) for the risk of acoustic neuromas
(Table 3). These increases are smaller than those found
by Hardell in the pooled analyses of his data alone
(Table 1), being “diluted” with the Interphone data cor-
responding to the requirements indicated above. Indeed,
by separating the overall OR data of these meta-analyses
according to their source [5,14,66,68], only Hardell’sO R
data are systematically > 1 (90-100%), 50-90% of which
are s.s., whereas Interphone data include 50-70% of OR
< 1, a proportion of which (up to > 20%) are s.s. More-
over, when only ipsilateral data are considered [67],
even 100% of the Interphone OR are > 1, 29% of which
are s.s. (Figure 2A, see additional file 7).
Also our meta-analyses of the literature data (Figures
3, 4, 5), limited to subjects with ipsilateral tumours and
MP latency ≥ 10 years (see additional file 8), show siz-
able and s.s. increases in risk of only ipsilateral acoustic
neuromas (over 70%) and astrocytomas (almost 60%)
compared to subjects not exposed to MP radiation, but
it should be noted that the overall figure for these meta-
analyses is strongly conditioned by the inclusion of the
Interphone data. The results of our meta-analyses con-
firm the need to identify the head tumour localisation
relative to the habitual head side of MP use, which is
exposed to 97-99% of the radiation; therefore, the failure
to identify the ipsilaterality of tumours adds an addi-
tional “dilution factor” to the risk evaluation.
Instead, the meta-analyses by Lloyd-Morgan [62] and
Kan [69], limited to a subset of the Interphone data and
without analysing tumour laterality or restricting refer-
ence to cases with MP use or latency ≥10 years, show a
prevalence (75%) of OR values < 1, partly (33%) s.s. for
the Interphone data, and an equal split of values < 1
and > 1 for Hardell’s data, 100% of those > 1 being s.s
(see additional file 7). The same pattern is shown by
Lahkola meta-analysis [70], based on a “targeted” choice
of data from the first US studies [36-38] and even from
a cohort study [59], as well as from certain Interphone
[41-43] and Hardell studies [8,9] (these latter data for
the main part selectively chosen). In fact, Lahkola [70],
besides including Hardell’s earlier data (1999, 2002, not
quoted in the present review) clearly lacking cases with
≥10-year latency time, calculated “through the pooling
of different exposures or tumor categories” moderate
Table 3 Results of the meta-analyses by Hardell, Kundi, and Kurana including Interphone data (≥ 10 year latency)
tumours all ipsilateral contralateral
astrocytomas I-IV ref. 14, 66 (338/511): 1.2; 0.8-1.9 (n.s.): 2.0; 1.2-3.4 (n.s.): 1.1; 0.6-2.0
″ 5 (233/330): 1.5; 1.2-1.8 (n.s.): 1.9; 1.4-2.4 -: not analyzed
″ 67 (233/330): 1.3; 1.1-1.6 (118/145): 1.9; 1.4-2.4 (93/150): 1.2; 0.9-1.7
neuromas ref. 14, 66 (83/355): 1.3; 0.6-2.8 (53/167): 2.4; 1.1-5.3 (30/151): 1.2; 0.7-2.2
″ 5 (67/311): 1.3; 0.95-1.9 (n.s.): 1.5; 1.1-2.5 -: not analyzed
“ 67 (67/311): 1.3; 0.97-1.9 (41/152): 1.6; 1.1-2.4 (26/134): 1.2; 0.4-1.03
meningiomas ref. 14, 66 (61/152): 1.3; 0.9-1.8 (20/46): 1.7; 0.99-3.1 (15/52): 1.0; 0.3-3.1
″ 5 (116/320): 1.1; 0.8-1.4 (n.s.): 1.3; 0.9-1.9 -: not analyzed
67 (116/320): 0.9; 0.7-1.3 (48/141): 1.1; 0.7-1.7 (36/164): 0.6; 0.4-1.03
95% s.s. data; n.s. = not specified.
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Page 7 of 15risks for >5-year latency of neuromas plus meningiomas
and of malign intracranial tumours from Hardell [8,9],
whereas the original Hardell’s much higher risks of
meningiomas, neuromas, and malign brain tumours for
>10 year latency were not included in Lahkola’s meta-
analysis.
The reasons underlying the discrepancy between
Hardell’s positive data and the negative Interphone find-
ings are seen clearly by close examination of the latest
articles from the two groups. Hardell [71] carried out a
new meta-analysis, which took into account the Inter-
phone data as well as his own: while the data overall do
not show any increase in head tumour risk in MP users,
limiting the meta-analysis to just ipsilateral tumours in
individuals with ≥ 10-year latency, a s.s. increase in risk
is found for gliomas (OR = 1.9; 95%CI = 1.4-2.4) and
for acoustic neuromas (OR = 1.6; 95%CI = 1.1-2.4).
Furthermore, while in Hardell’s data > 90% of OR values
are > 1, for the main part (>50%) s.s., this is the case for
the Interphone data only when the analysis is limited to
ipsilateral tumours in individuals with ≥ 10-year latency:
90% of OR values > 1, 22% of which s.s. (Figure 2B, see
additional file 9).
In the first “official” Interphone Study Group [72],
considering gliomas and meningiomas, the prevalence of
OR values < 1 is notable (almost 80%), over 30% of
these being s.s. (Figure 2C). Obviously, also this study is
characterized by the usual bias and flaws:
￿ the low participation of cases (78% for meningiomas:
range 56-92%; 64% for gliomas: range 36-92%), and
especially of controls (53%: range 42-74%);
￿ the low median lifetime cumulative call time: 75 h
for meningiomas (median: 2 h/month, i.e. 4 min/day),
and 100 h for gliomas (median: 2.5 h/month, i.e. 5 min/
day);
￿ the low percentage of cases with ≥ 10 y since the
start of ipsilateral MP use: 3% of meningiomas, and
6.5% of gliomas.
However, analysis limited to subjects with “highest
cumulative call times” shows a marked prevalence of
OR values >1 [90% for meningiomas, and 100% for
gliomas (20% s.s.)] (Figure 2C, see additional file 9).
Moreover, given the selection bias due to the under-
representation of never users among controls, an ana-
lysis was carried out with short-term users as controls.
In this analysis, the OR values for glioma are almost
Figure 2 Data from Hardell and Interphone meta-analyses: percentage of the OR values > 1 or < 1, and percentage of those
statistically significant.
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Page 8 of 15all > 1, 30% of which s.s. with a dose-response rela-
tionship, showing that those who used MPs for ≥ 10
years are twice as likely to develop a brain tumour,
especially in the ipsilateral side (OR = 1.96; 95%CI =
1.22-3.16) compared to total tumours (OR = 1.82; 95%
CI = 1.15-2.89) and contralateral tumours (OR = 1.25;
95%CI = 0.64-2.42) (Table five of the Interphone text,
and Table in its Appendix 2 online), just what is
expected in the case of MPs having oncogenic action.
This should rule out the possibility of the increase in
risk of head tumours in high MP users, and indeed the
increase in gliomas, acoustic neuromas and parotid
gland tumours reported in some Interphone studies
(Table 2), being due to methodological bias and con-
founding factors.
The conclusive report from Interphone [72] was
accompanied by a commentary [73] whose title is very
telling - “Call me on my mobile phone ... or better not?
- a look at the Interphone study results”, which pointed
out some of the chief bias highlighted in the present
report. Our analyses strongly reduces the uncertainty of
the response to the quoted question: “better not” !
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Figure 4 Meta-analyses on data on meningiomas after ≥ 10-
year latency.
-
-
-
-
-
-
-
-
-
-
-
-
-
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-
-
-
Figure 3 M e t a - a n a l y s e so nd a t ao ng l i o m a sa f t e r≥ 10-year
latency.
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expressed disagreement with the reassuring interpreta-
tion of the Interphone results, which essentially indi-
cates a lack of cause for alarm [72]. In September 2009,
before the US Senate [74], Sadetzki defended the validity
of her results showing an increase in risk of parotid
tumour in strong cell-phone users, particularly in rural
areas [53]. Finally, an editorial by Cardis, former Inter-
phone coordinator, and by Sadetzki - also under a
highly significant title “Indications of possible brain-
tumour risk in mobilie-phone studies: should we be
concerned?” [75] - gives a careful discussion of a selec-
tion of Hardell’s main papers [1,2,10], noting that these
show an increase in cerebral tumour risk in people
using MPs for relatively long periods, and recognizes
that the Interphone research contains a number of bias
that lead to large underestimation of the risk values,
among which some of those highlighted in the present
report.
On the other hand, the editorial points out a number
of observations supporting the risk:
￿ a 40% increase risk for glioma in the highest decile
of cumulative call time;
￿ the increase of risk with time since start of use, sug-
gesting a true effect of mobile-phone use;
￿ the increased risk of tumours in the temporal lobe in
the highest decile of cumulative time.
The authors conclude that “the overall balance of the
aboved-mentioned arguments suggests the existence of a
possible association” between MP exposure and
increased head tumour risk.
Discussion
Previous studies identified a number of study design
flaws and bias that give rise to underestimation of the
real risk in epidemiological studies, particularly in those
funded by industries [76,77]. The present paper, which
concerns one of the most presently controversial debate
- the possible relationship between MP use and
increased risk of head tumours - shows that the negative
results produced by studies funded by the cell-phone
companies are affected by many biases and flaws, giving
rise to a systematic underestimate of the risk. On the
contrary, studies producing positive results - without
errors and financial conditioning - indicate a cause/
effect relationship supported by biological plausibility.
It must be noticed that the s.s. increase in malignant
brain tumour risk repeatedly reported by Hardell among
long-term MP users [1-3] is supported by the age-
adjusted incidence increase of such tumours in Sweden
[78]: during 1970-2007 the annual age-adjusted increase
for all brain tumours was + 0.28% (95%CI = + 0.04 to +
0.52), whereas during 2000-2007 the figure for astrocy-
tomas was + 1.55 (95% CI = - 0.15 to + 3.27, and even
higher and s.s. in the age group > 19 years (+ 2.16; 95%
CI = + 0.25 to 4.10). In addition, the s.s. increase in the
risk of parotid gland malignant tumours reported by
Sadetzky in cell-phone users [53] is supported by the
incidence increase of such tumours in Israel [79]: the
mean annual incidence of parotid cancers increased 4-
fold from 1970 (16 cases/year) to 2006 (64 cases/year),
whereas the incidence of other salivary gland tumours
remained stable. The steepest increase in parotid can-
cers occurred after 2001, with an average of 37 cases
annually before that date, and 61 cases per year
-
-
-
-
-
-
-
-
-
-
-
-
Figure 5 Meta-analyses on data on acoustic neuromas after ≥
10-year latency.
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due to population growth as the population of Israel
i n c r e a s e d2 . 1 - f o l df r o m1 9 7 0t o2 0 0 1 ,b u to n l y1 . 1 - f o l d
from 2001 to 2006. The above data seem to indicate
that, starting from 2000-2001, a new factor capable of
increasing the risk of malignant head tumours among
MP users began to manifest its effect, which is in accor-
dance with the ≥ 10-15 years latency reached by cellular
and cordless phone users in those years in both Sweden
and Israel (see Background).
There are many bias and flaws in the Interphone and
similar studies that lie behind the large prevalence of OR
values < 1 in the overall results, giving rise to a systematic
underestimate of the risk [78,80-84] whereas the protocol
by Hardell producing positive results is without apparent
errors or financial conditioning (Table 4), the results
indicating a cause-effect relationship supported by biolo-
gical plausibility [17-34]. A review on health effect of
MPs showed that the studies reporting one or more s.s.
positive results were funded by public bodies, while stu-
dies funded exclusively by industries were seven fold less
likely to report at least one such result, and the difference
between the two sets of data was highly s.s. [35]. Accord-
ing to the authors “this study indicates that the interpre-
tation of the results from existing and future studies ...
should take sponsorship into account”.
Likewise, the discrepancy between the positive data of
Hardell and the negative data from Interphone is high-
lighted by the authors that performed a random-effect
model meta-analysis of 24 case-control studies [85].
These authors observed a s.s. positive association
between MP use and increased head cancer risk in 10
studies ("high-quality studies”,i n c l u d i n g7s t u d i e sb y
Hardell, only 1 by Interphone, and 2 by other groups),
whereas a negative association (i.e. an apparent “protec-
tive effect”) was observed in 14 studies ("low-quality stu-
dies”, including 12 by Interphone, and 2 by other
groups). Elements in the method used to evaluate the
“quality” of the studies were: a) blind or non-blind pro-
tocol; b) presence or absence of participation and selec-
tion bias of cases and controls; c) relevant or marginal
MP exposure; d) adequate or inadequate latency or
overall time of MP use; e) scrutiny of tumour laterality;
f) funding by independent sources or by cell-phone
companies. The authors make the following conclusion:
“We feel the need to mention the funding sources for
each research group because it is possible that these
may have influenced the respective study designs and
results”.
The Hardell group was supported only by grants from
Public Bodies, whereas the Interphone-related studies by
the Quality of Life and Management of Living Resources
program of the European Union and the International
Union Against Cancer; but the latest received funds for
those studies from the Mobile Manufacturers Forum
and the Global System for Mobile Communication
Association [86]. According to the Interphone protocol
[86], “the partial funds provided by the above cell-phone
Associations to the International Union Against Cancer
complement funds from non-commercial sources
including the European Union and national local
research funding organization”,b u t“provision of funds
Table 4 Errors in negative Interphone studies [4,36-55,65,72], and reliability of positive Hardell studies
[1-3,7-10,64,71,78]
study, design, methods negative studies positive studies
Mobile phone use inadequate: 2-5 min/day significant: 16-32 min/day
Latency time <5% cases with latency ≥10 y >18% cases with latency ≥10 y
Cordless phone users considered unexposed considered exposed
Ipsilateral tumour latency ≥10 y for only 2% cases ≥10 y for >16% cases
Head tumours identified only gliomas, meningiomas, neuromas, parotid tumours also other head tumours types
Deceased cases not included included: proxy interviews
Interviews not blind always double blind
Type of interviews face-to-face mailed questionnaires
Time of interviews cases: during hospitalisation cases: after hospitalisation
controls: at home controls: at home
Exposure assessment non blind interview blind questionnaire
Data processing not stated (not blind?) Blind
Laterality attribution bias present Absent
Delayed interviews for controls compared to cases not delayed
Participation reduced up to 40% always near to 90%
Selection exposed controls prevail no selection bias
Documentation positive data ignored no documentation bias
Funding co-funded by MP Companies funded only by Public Bodies
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Page 11 of 15to the Interphone study investigators via the Interna-
tional Union Against Cancer is governed by agreements
that guarantee Interphone’s complete scientific indepen-
dence”,a n d“the funders of the Interphone studies do
not have access to any results of the studies before their
publication. They may, however, be informed, together
with representatives of other concerned organizations
such as consumer groups, a maximum of seven days
before the publication of the results, under strict terms
of confidentiality”.
In addition to the above funds, several authors partici-
pating in the Interphone study received additional fund-
ing from their national MP companies [43,44,47,51,63] or
by other private companies [42,59,60], such that a sub-
stantial portion of the Interphone Study funding came
from the cell-phone industry. These additional funds are
not specified in the Interphone protocol [86], and the
agreements regulating access to the experimental results
and the control of their use by the array of national cell-
phone and other private companies involved are not
known. Furthermore, other negative studies quoted in
the present article have been supported by the mobile
phone industry, for example the two Muscat studies
[36,37] (Cellular Industry Telecommunications Associa-
tion via the Wireless Technology Research) [19,62], the
Johansen study [59] (TeleDanmark Mobil, Sonofon and
the International Epidemiology Institute, a private com-
pany operating as a cell-phone industry adviser), and the
Morgan study [58] (Motorola).
Nevertheless, of the authors of the above negative stu-
dies, 14 [36,37,39-44,46,50,53,54,58,59] do not make any
declaration about conflict of interest, 3 [47,48,52] state
“conflict of interest: none declared” (it is not clear
whether this is from the authors or from the editor),
while 4 [45,49,51,55] declare “conflict of interest: none”.
Also the European Environment Agency [87], the Eur-
opean Parliament [88], and two recent papers [89,90]
have expressed preoccupations about the effects on
human health, particularly on that of young people, by
the continuous RF exposure produced in public places
and at home by wi-fi for internet access and MP use.
The European Parliament has also pointed at “the need
to evaluate scientific integrity of the authors, in order to
forestall possible risks, conflicts of interest or even
frauds which tend to arise in a context of growing com-
petition among researchers” [88].
Conclusions
Our examination of the literature data, together with the
results of our and other’s meta-analyses, lead to the con-
clusion that even today the risk of head tumours resulting
from MP use is very high. Lloyd-Morgan, while underesti-
mating by 50% the number of cell users, without consider-
ing cordless users and assuming a minimum latency time
of 30 years, calculates “there would be about 1900 cell-
phone-induced brain tumours out of about 50,000 brain
tumours diagnosed in 2004, increasing to about 380,000
cell-phone-induced brain tumours within 2019 in the USA
alone”, which would require “an increase in health costs of
an annual US$ 9.5 billion and the need for a 7-fold
increase in number of neurosurgeons”. An estimate of the
incidence of head tumours must begin with the correct
number of cell-phone users (5 billion subscriptions world-
wide at mid 2010), should also consider the risk to cord-
less users, and assume at least a doubling of the incidence
of head tumours and of acoustic neuromas as documented
by Hardell already after a latency of at least 10-15 years.
Most likely, a number of factors raise our concern still
further - for example, the latency of head tumour
induced by MPs can exceed 30 years; risk is higher in
those starting MP use when young and who have not
yet accumulated 10 years of latency; there is a continued
rise in MP use by youngsters, attracted to new offers
from the MP companies (photography, listening to
music, videophony, internet, etc.); the data of Hardell on
the increase in other types of malign and benign head
tumour- besides brain gliomas, astrocytomas, and acous-
tic neuromas - are for the main part today only indica-
tive. Therefore, today we are evaluating just the tip of
an iceberg, and will have to wait one or two decades
before its real dimensions come to light. But it is clear
t h a tt h ea n a l y s i sw eh a v ep r e s e n t e da l r e a d ys h o w sa
clear increase in tumour risk, and - if it proves even
partly founded - the use of MPs could lead to a health
crisis of dramatic proportion.
Furthermore, the recent editorial by Cardis and
Sadetzky about the conclusive Interphone report states
that “There are now more than 4 billion people, includ-
ing children, using mobile phones. Even a small risk at
the individual level could eventually result in a consider-
able number of tumours and become an important pub-
lic-health issue. Simple and low-coast measures, such as
the use of text messages, hands-free kits and/or the
loud-speaker mode of the phone could substantially
reduce exposure to the brain from mobile phones.
Therefore, until definitive scientific answers are avail-
able, the adoption of such precautions, particularly
among young people, is advisable”.
While recognizing that mobile telephony is an out-
standing technology of inestimable value, responsible
science must raise awareness of the risks involved.
We thus conclude that already today there is sufficient
epidemiological evidence to warrant application of the
precautionary principle aimed at:
￿ setting exposure limits that are precautionary;
￿ limiting the spread of wireless technology in schools
and highly frequented places (libraries, offices, hospital
wards);
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exposure to MPs, with low-cost voluntary options ("pru-
dent avoidance”) based on the caution in the use of
MPs. A 10-point list of simple personal actions designed
to substantially reduce the exposure to cell-phone radia-
tion was produced by Viennese Medical Officers in
2006, adopted in the same year by the French Agency
on Radiofrequencies http://www.sante-radiofrequences.
org, by several study groups [[17-19], also http://www.
devradavis.com.
￿ awareness-raising in schools through a campaign on
the use of the various wireless transmission
technologies;
￿ discouraging the use of MPs by minors under 14
years;
￿ epidemiological monitoring of the possible onco-
genic action of home and workplace EM exposures.
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